Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.47 |
| ▸ | SLC6A12 | P48065 | 5/20 | 0.45 |
| ▸ | SLC6A11 | P48066 | 5/20 | 0.45 |
| ▸ | SLC6A13 | Q9NSD5 | 5/20 | 0.45 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17429993 | 1.00 | ANPEP (0.47) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL503733 | 1.00 | ANPEP (0.47) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL10952451 | 0.93 | ANPEP (0.43) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL10952455 | 0.93 | ANPEP (0.43) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL10851234 | 0.93 | ANPEP (0.43) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL11798174 | 0.91 | ANPEP (0.42) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL24197646 | 0.87 | ANPEP (0.56) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL24483431 | 0.87 | ANPEP (0.56) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL74792 | 0.87 | — | — | |
| SCHEMBL431287 | 0.87 | ANPEP (0.56) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242486-A1 | PYRIDINYL MORPHOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-06-07 | — | — | US | disclosed |
| US-9867811-B2 | Method of treating atherosclerosis in high triglyceride subjects | NOVARTIS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| US-9550741-B2 | Benzoisothiazole compounds and methods of treating schizophrenia | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2017-01-24 | — | — | US | disclosed |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160096811-A1 | BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS | SHANAGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2016-04-07 | — | — | US | disclosed |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-01-21 | — | — | US | disclosed |
| US-20150164912-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2015-06-18 | — | — | US | disclosed |
| US-20140134262-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2014-05-15 | — | — | US | disclosed |
| US-20140038944-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2014-02-06 | — | — | US | disclosed |
| US-8552202-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2013-10-08 | — | — | US | disclosed |
| US-20130150345-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
| US-8389737-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| EP-2283022-B1 | FURO [3, 2-B]PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-07-18 | — | — | EP | disclosed |
| EP-2283022-A1 | FURO Ý3, 2-B¨PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | Amura Therapeutics Limited (GB) | 2011-02-16 | — | — | EP | disclosed |
| US-20110009386-A1 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| WO-2009112826-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| US-20090075968-A1 | CETP inhibitors | SAKAKI JUNICHI | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150345-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | ANPEP 470/4885ENPEP 1039/4885SLC6A12 2400/4885 |
| US-20230242486-A1 | PYRIDINYL MORPHOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HTR2C, HTR3D, HTR5A | ANPEP 3811/4885ENPEP 4687/4885SLC6A12 235/4885 |
| US-20140134262-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | CETP, MTTP, APOB | ANPEP 1757/4885ENPEP 502/4885SLC6A12 3829/4885 |
| US-20160096811-A1 | BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS | HTR3A, SLC6A3, HTR5A | ANPEP 3131/4885ENPEP 4160/4885SLC6A12 588/4885 |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | ANPEP 390/4885ENPEP 824/4885SLC6A12 2507/4885 |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | ANPEP 470/4885ENPEP 1039/4885SLC6A12 2400/4885 |
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | CETP, MTTP, APOB | ANPEP 1910/4885ENPEP 588/4885SLC6A12 3962/4885 |
| US-20150164912-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | ANPEP 470/4885ENPEP 1039/4885SLC6A12 2400/4885 |
| US-20140038944-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | ANPEP 470/4885ENPEP 1039/4885SLC6A12 2400/4885 |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | ANPEP 416/4885ENPEP 554/4885SLC6A12 934/4885 |
| US-20110009386-A1 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | ANPEP 390/4885ENPEP 824/4885SLC6A12 2507/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | ANPEP 416/4885ENPEP 554/4885SLC6A12 934/4885 |
| US-20090075968-A1 | CETP inhibitors | CETP, PCSK9, MTTP | ANPEP 519/4885ENPEP 243/4885SLC6A12 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.